Navigation Links
Chrysalis BioTherapeutics, Inc., Receives $1.5m from the National Cancer Institute to Mitigate Radiotherapy-Induced Brain Tissue Damage
Date:9/23/2013

GALVESTON, Texas, Sept. 23, 2013 /PRNewswire/ -- Today, Chrysalis BioTherapeutics, Inc., announced receipt of a $1.5m contract from the National Cancer Institute (NCI) to continue its development of Chrysalin® to mitigate radiotherapy-induced damage to normal brain tissue. Radiotherapy is a primary tool for controlling tumor growth, yet damage to surrounding normal tissues limit the amount of radiation that can be used to kill tumors. Moreover, side-effects of radiotherapy can have long lasting effects on patients especially in the brain where radiation can affect learning, memory and physical functions. 

(Logo: http://photos.prnewswire.com/prnh/20130919/MM83393LOGO)

According to SEER Cancer Statics, nearly one in 161 people will be diagnosed with brain or nervous system cancer during their lifetime. Finding ways to mitigate damage from radiotherapy or restore neural function following radiotherapy may allow more effective cancer treatment to increase survival and improve quality-of-life for survivors.

This project is a collaboration between Chrysalis BioTherapeutics, Inc., Baylor College of Medicine (BCM), and the University of Texas Medical Branch (UTMB). Pre-clinical results indicate that Chrysalin® treatment restores radiation-damaged neural integrity and promotes neurogenesis in the hippocampus. "These effects of Chrysalin® may be very important," said Dr. Mostafa Waleed Gaber, Associate Professor at Baylor College of Medicine and Co-Director of the Small Animal Imaging Facility at Texas Children's Hospital, "especially in children where successful radiotherapy treatment of brain tumors may have life-long effects on cognitive function."

Chrysalin® is a naturally occurring regenerative peptide that is being developed by Chrysalis BioTherapeutics under world-wide license from UTMB to mitigate effects of nuclear radiation and radiotherapy.  "If we can reduce side effects of radiotherapy in the brain and other tissues, we can use more effective radiotherapy protocols to kill tumors, save lives, and improve quality-of-life." said Dr. Darrell Carney, CEO of Chrysalis BioTherapeutics, Inc.

About Chrysalis.   Chrysalis is a privately held early-clinical-stage biopharmaceutical company developing a thrombin peptide drug platform to mitigate effects of radiation, improve tissue regeneration, and treat myocardial and cardiovascular disease.  Chrysalin® was originally developed by Dr. Carney at UTMB and has been tested in human clinical trials (dermal healing and bone fracture repair) with no adverse side effects. For more information on Chrysalis visit http://www.chrysbio.com.

Media Contact: Kira Blackwell, 409-497-4083, kblackwell@chrysbio.com

This research is fully funded by the National Cancer Institute.  For more information on the NCI, visit http://www.cancer.gov/.        


'/>"/>
SOURCE Chrysalis Biotherapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Northwest Biotherapeutics, Inc. Announces Full Exercise of Over- Allotment Option
2. Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers
3. Senior Executives of Cytyc Corporation, and Constitution Medical, Inc., Announce the Launch of ATON PARTNERS
4. An Open Letter from Sterling Scott, CEO, GrowLife, Inc., Regarding the DOJ Position Change Regarding Marijuana
5. Signature Therapeutics, Inc., Presents Four Scientific Posters Today at PAINWeek 2013 Meeting
6. Neurotrope, Inc., Announces Reverse Merger and Completion of $21.9 Million Private Offering
7. National coordinated health care and health IT transformation event will be hosted by OCHIN, Inc., the Oregon Medical Association, and Oregon Health Network: The cHealth Innovation Symposium
8. Morning Research: BioCryst Pharma Inc., Questcor Pharma Inc., PDL BioPharma Inc., and Amgen Inc.
9. MELA Sciences, Inc., A Leader In The Fight Against Melanoma, Hosts Symposium At 8th World Congress Of Melanoma
10. Astute Medical, Inc., veranstaltet Symposium aus anlaß des Critical Care Nephrology Kongress
11. Pioneering Medical Technology Company, Optivus Proton Therapy, Inc., Celebrates 20th Anniversary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Lilly and Company (NYSE: LLY ) today ... at the 9 th Clinical Trials on Alzheimer,s ... meet the primary endpoint in the EXPEDITION3 clinical trial, ... dementia due to Alzheimer,s disease (AD), and Lilly will ... of mild dementia due to AD. ...
(Date:12/8/2016)... DUBLIN , Dec 8, 2016 Research ... Electrodes Market Analysis and Trends - Adhesion Type, Application, Usability - ... ... The Global Cardiology Electrodes Market is poised to grow at a ... prominent trends that the market is witnessing include advancements in extracellular ...
(Date:12/8/2016)... 8, 2016   TriNetX , the health ... Hospital signed a membership agreement to join ... of new cures. The TriNetX network ... million patients globally, biopharmaceutical companies and contract research ... protocol design, site selection, patient recruitment, and collaborative ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... The ... the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. ... safety. Only a few hospitals and facilities have earned this distinction. This is ...
(Date:12/8/2016)... ... December 08, 2016 , ... Russ ... announced the first national #QuackGivesBack campaign which supported local breast cancer organizations during ... franchise-wide Quack Gives Back initiative, and we’re very pleased with the ...
(Date:12/8/2016)... Pa. (PRWEB) , ... December 08, 2016 , ... ... Medicine Southern Chester County, a Property owned by an affiliate of Seavest, has ... square foot Penn Medicine Southern Chester County ambulatory care center (ACC) was named ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... CURE Media ... centers and advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat ... the announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored to team ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , ... Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont ... and attorneys from the firm’s global Life Sciences & Medical Technology Group have been ...
Breaking Medicine News(10 mins):